Document Type: Research Articles
Health Sciences Research Center (HSCR), Princess Nourah bint Abdulrahman University (PNU), Kingdom Saudi Arabia.
Department of Biology, Princess Nourah bint Abdulrahman University (PNU), Kingdom Saudi Arabia.
Department of Medicine, Oncology Centre, King Khalid University Hospital, King Saud University, Kingdom Saudi Arabia.
Department of Molecular Biology, Princess Nourah bint Abdulrahman University (PNU), Kingdom Saudi Arabia.
Central Labe, King Saud University Riyadh, Kingdom Saudi Arabia.
Faculty of Medicine, EL-Azher University and Specialist Physician, Oncology Clinic-Medical Affaies, Tawam Hospital, AL Ain, UAE.
Background: Due to the prevalence of Hepatocellular carcinoma (HCC) in Saudi Arabia, using new markers to
give best diagnostic performance than alpha-feto protein (AFP) are important in early diagnosis. The aim of this work
was to compare the significance between serum and mRNA Golgi glypican73 (GP-73) as newly identified diagnostic
and prognostic markers for HCC among Saudi patients. Materials and Methods: A total of 300 subjects were divided
into: 250 blood samples where 145 samples from HCC, 105 samples from chronic liver cirrhosis (CLC) and 50 normal
controls were investigated for serum GP73 (sGP73) by ELISA. GP-73 mRNA from peripheral blood mononuclear cells
was amplified by RT-PCR. The sensitivity and specificity of both techniques was compared. Results: Serum Golgi
glypican 73 was significantly higher in HCC group compared to cirrhotic and normal controls (p<0.001). Sensitivity
and specificity were 95% for sGP-73, 100% and 90% for Golgi glypican 73 mRNA. The combination of sensitivity
between AFP and sGP73 was 80% and 95% respectively. Conclusion: Both serum Golgi glypican-73 and GP-73Mrna
are good diagnostic biomarkers for early detection of HCC in Saudi patients. RT-PCR is more accurate and sensitive
(100%) than ELISA (95%) in detecting Golgi glypican 73.